Press Releases May 5, 2026 07:00 AM

Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference

Fractyl Health Schedules Q1 2026 Financial Results Release and Investor Conference Presentation

By Marcus Reed GUTS

Fractyl Health, a clinical stage metabolic therapeutics company focused on innovative treatments for obesity and type 2 diabetes, will announce its Q1 2026 financial results and provide business updates on May 12, 2026. Additionally, CEO Dr. Harith Rajagopalan will present at the BofA Securities 2026 Health Care Conference on May 14, 2026.

Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference
GUTS

Key Points

  • Fractyl Health will report its first quarter 2026 financial results and business update on May 12, 2026.
  • CEO to present at a major healthcare investor conference, highlighting the company's focus and pipeline.
  • The company is advancing novel metabolic therapeutics aimed at treating obesity and type 2 diabetes, potentially impacting healthcare and biotech sectors.

BURLINGTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company), a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced that it will report financial results for the first quarter 2026 and provide business updates on Tuesday, May 12, 2026, at 4:30 p.m. ET.

A live webcast of the conference call and presentation can be accessed in the “Events” section of Fractyl Health’s website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event.

The Company also announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of Fractyl Health, will present at the BofA Securities 2026 Health Care Conference on Thursday, May 14, 2026, at 9:20 a.m. PT (12:20 p.m. ET).

A live webcast of the presentation can be accessed in the “Events” section of Fractyl Health’s website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event.

About Fractyl Health        

Fractyl Health is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes. Our Revita® and Rejuva® candidates are designed to target root causes of metabolic diseases, allowing us to advance metabolic disease treatment from chronic management towards prevention and reversal of disease. Fractyl is headquartered in Burlington, Massachusetts.

Contact

Brian Luque, Head of Investor Relations and Corporate Development
[email protected], 951.206.1200


Risks

  • The company is clinical stage, indicating products are not yet approved and carry development and regulatory risks.
  • Financial performance details are pending release, which may impact investor sentiment.
  • Market competition and challenges in metabolic disease treatment advancement pose ongoing uncertainties.

More from Press Releases

NMI Holdings, Inc. to Participate in Upcoming Investor Conferences May 12, 2026 Fervo Energy Announces Pricing of its Upsized Initial Public Offering May 12, 2026 Titan Mining Delivers 22% Revenue Growth and Expands U.S. Critical Minerals Platform with Graphite Production May 12, 2026 Anteris Announces Results for the First Quarter of 2026 May 12, 2026 Copa Holdings Announces Monthly Traffic Statistics for April 2026 May 12, 2026